Defective Estrogen Receptors in Human Mammary Cancers: Their Significance in Defining Hormone Dependence1

Raam, Shanthi; Robert, Nicholas J.; Pappas, Constantine A.; Tamura, Hisashi

doi:10.1093/jnci/80.10.756

Cited by 33 publications

(17 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This could be because pS2 expression may reflect a genuinely oestrogen-sensitive tumour (Schwartz et al, 1991). In keeping with this is the experimental (Johnson et al, 1989) and clinical evidence that pS2 expression predicts a subsequent response to hormonal manipulation initially (Skilton et al, 1989;Schwartz et al, 1991;Henry et al, 1990;Ramm et al, 1988;Henry et al, 1988) and on relapse (Henry et al, 1991;Schwartz et al, 1991). Since only 50%-65% of oestrogen receptor-positive tumours actually respond to anti-oestrogen therapy (Stack et al, 1988), we concur that pS2 may be more useful than oestrogen receptor measurement in predicting response to endocrine therapy (Predine et al, 1992).…”

Section: Discussionmentioning

confidence: 77%

pS2 is an independent factor of good prognosis in primary breast cancer

Thompson¹,

Hawkins²,

Elton³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

Summary In breast cancer, oestrogen regulated genes, such as pS2, may be expressed in well differentiated tumours with a good prognosis. We have examined pS2 mRNA expression in 78 primary, untreated breast cancers and related pS2 expression to disease behaviour and known prognostic factors. pS2 mRNA expression was detected in 25/78 (32%) of cancers and was significantly associated with a moderate/high oestrogen receptor content (P = 0.045, Chi Square test). pS2 mRNA expression was associated with freedom from disease at median 31 months clinical and radiological follow-up (P = 0.015, Fisher's exact test, odds ratio 8.6).Using multiple logistic regression analysis of six potential prognostic factors only pathological axillary node status (P<0.01) and pS2 mRNA expression (P<0.05) provided independent prognostic information. Furthermore, pS2 was associated with a good prognosis in the axillary node positive patients where only 1/13 (8%) with pS2 mRNA expression compared with 13/29 (45%) without detectable expression had recurrence of their disease. These data provides strong support for pS2 as a useful independent prognostic factor in primary breast cancer.

show abstract

Section: Discussionmentioning

confidence: 77%

pS2 is an independent factor of good prognosis in primary breast cancer

Thompson¹,

Hawkins²,

Elton³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

show abstract

“…Numerous mechanisms explaining this resistance have been suggested, including crosstalk with or increased expression of components of growth receptor pathways, especially those belonging to the epidermal growth factor superfamily or to insulin growth factor receptors. other postulated mechanism include aberrant activation of other growth factor signaling pathways, overexpression of myc, cycline e1, and cycline D1, epigenetic modification, as well as mutations, deletions, and truncations in the ERα gene (30)(31)(32)(33)(34)(35). In the presence of a nonfunctional er, Ar may be the primary driver of downstream signaling for cell growth (36).…”

Section: Discussionmentioning

confidence: 99%

Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis

Vera‐Badillo

Templeton

Gouveia

et al. 2013

JNCI Journal of the National Cancer Institute

292

262

View full text Add to dashboard Cite

“…Tamoxifen is used to treat estrogen receptor-positive breast cancers because it competes with estradiol for es trogen receptors and then the tamoxifen-receptor com plex binds to nuclear acceptor sites for extended periods of time [22][23][24], This action renders the tissue refractory to the proliferative effect of estradiol until more receptors are made available again [251. Tamoxifen has also been shown to interact with other binding sites in the cell and has many effects that arc apparently not mediated through the steroid receptors.…”

Section: Introductionmentioning

confidence: 99%

Estradiol Augments while Tamoxifen Inhibits Rat Mast Cell Secretion

Vliagoftis

Dimitriadou

Boucher

et al. 1992

Int Arch Allergy Immunol

Self Cite

150

View full text Add to dashboard Cite

Mast cells have been studied extensively for their involvement in allergic reactions, where they secrete numerous powerful mediators in response to immunoglobulin E and specific antigens. However, they are also triggered by neuropeptides, they have been found in close contact with neurons, and they are activated in diseases such as angioedema, interstitial cystitis and irritable bowel disease, the prevalence of which is much higher in women. When tested on purified rat peritoneal mast cells, 17β-estradiol augmented secretion of histamine and serotonin, starting at 1 μM and in a dose-dependent manner, whether stimulated by the mast cell secretagogue compound 48/80 or the neuropeptide substance P. However, 17β-estradiol did not augment mast cell secretion stimulated by immunoglobulin E and specific antiserum indicating that immunologic stimulation is under different regulation. Testosterone inhibited secretion induced by compound 48/80. Tamoxifen, an estrogen receptor antagonist used in the treatment of breast cancer, inhibited serotonin and histamine release from purified rat peritoneal mast cells triggered by compound 48/80 or substance P. Tamoxifen also inhibited the increase in intracellular free Ca²⁺ originating from an influx of extracellular Ca²⁺ in response to compound 48/80. Moreover, tamoxifen antagonized the synergistic effect of phorbol myristate and the cation ionophore A23187 on mast cell secretion, suggesting that tamoxifen’s inhibition may be due to regulation of protein kinase C activity. Tamoxifen may, therefore, have a beneficial effect in other neuroimmunoendocrine disorders both through estrogen receptor blockade and inhibition of mast cell secretion.

show abstract

Defective Estrogen Receptors in Human Mammary Cancers: Their Significance in Defining Hormone Dependence1

Cited by 33 publications

References 0 publications

pS2 is an independent factor of good prognosis in primary breast cancer

pS2 is an independent factor of good prognosis in primary breast cancer

Androgen Receptor Expression and Outcomes in Early Breast Cancer: A Systematic Review and Meta-Analysis

Estradiol Augments while Tamoxifen Inhibits Rat Mast Cell Secretion

Contact Info

Product

Resources

About